F-18 Florastamin - FutureChem/HTA Co/IASON/Moltek
Alternative Names: 18F labeled FC303 injection; 18F-FC303; [18F]FLOR (FC303) injection; [18F]FLOR (FC303) PET/CT imager; [18F]Florastamin; Florastamin 18FLatest Information Update: 29 Sep 2024
Price :
$50 *
At a glance
- Originator FutureChem
- Developer FutureChem; HTA CO; IASON
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Prostate cancer
Most Recent Events
- 29 Sep 2024 Phase I development in Prostate-cancer (Diagnosis) is still ongoing (Futurechem pipeline, September 2024)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in USA (IV, Injection)
- 21 Aug 2023 Phase-III clinical trials in Prostate cancer (Diagnosis) in China (IV) (NCT06011304)